PepGen Inc. (NASDAQ: PEPG)

PepGen Inc., a clinical-stage biotechnology company, is at the forefront of advancing the next generation of oligonucleotide therapeutics to revolutionize the treatment of severe neuromuscular and neurological diseases. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform is built on over a decade of research and development, utilizing cell-penetrating peptides to enhance the uptake and activity of conjugated oligonucleotide therapeutics.

PepGen's primary business activities revolve around the development of innovative therapeutic solutions for debilitating diseases such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company operates in the biotechnology industry and conducts its research and clinical trials in various countries, including the United States, Canada, and the United Kingdom.

The company generates revenue primarily through the development of its product candidates, which include PGN-EDO51 for DMD and PGN-EDODM1 for DM1. PGN-EDO51 facilitates the skipping of exon 51, allowing the synthesis of a shortened yet functional dystrophin, thereby addressing the underlying genetic mutations found in DMD. In a Phase 1 clinical trial, PGN-EDO51 resulted in the highest levels of mean exon skipping in humans following a single dose compared to publicly available data for other DMD exon 51-skipping approaches.

PepGen holds a competitive advantage in the industry through its EDO platform, which has demonstrated enhanced delivery of PMO to additional tissues that remain challenging to penetrate with existing technologies. This platform has the potential to deliver multiple classes of nucleic acid payloads, including other oligonucleotide therapeutics, and the company is currently exploring new cargos and peptide technologies.

Although the text does not provide specific names of customers, it does mention key competitors in the industry, such as Pfizer Inc. and Sarepta, which are also developing gene therapies for DMD.

PepGen's portfolio includes five programs, two of which are clinical and three are preclinical. The company's current pipeline comprises PGN-EDO51, PGN-EDODM1, and three additional preclinical stage programs. PepGen is initially focused on addressing neuromuscular indications and is building a portfolio of therapeutic candidates to address the underlying genetic mutations found in DMD and DM1.